Mizuho Securities USA’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Mizuho Securities USA’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,750	Closed	-$600K	–	168
2018 Q3	$600K	Buy	+4,750	New	+$503K	0.05%	114
2016 Q3	–	Sell	-6,900	Closed	-$984K	–	238
2016 Q2	$984K	Buy	+6,900	New	+$1.01M	0.16%	86

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mizuho Securities USA's ICPT Position: Q4 2018 in Review

Mizuho Securities USA sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 4,750 shares — an estimated $600K sold.

Mizuho Securities USA first reported a position in ICPT in Q2 2016 and held it in 2 quarters. The position peaked at $984K in Q2 2016. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

Mizuho Securities USA reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Mizuho Securities USA sold 4,750 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $600K.
Mizuho Securities USA first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
Mizuho Securities USA's Intercept Pharmaceuticals, Inc. position peaked at $984K in Q2 2016.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on Mizuho Securities USA's 13F filing for Q4 2018, filed 4 Feb 2019.